Silicon Agent and Ulcerative Colitis in Mice
A new therapy against ulcerative colitis via the intestine and brain using the Si-based agent
Research hubs: Brain & Nervous System
This research was done in animals. Results in animals often don't carry over to people.
- Evidence type
- Animal study (mouse)
- Authors
- Yoshihisa Koyama, Yuki Kobayashi, Ikuei Hirota, Yuanjie Sun, Iwao Ohtsu, Hiroe Imai, Yoshichika Yoshioka, Hiroto Yanagawa, Takuya Sumi, Hikaru Kobayashi, Shoichi Shimada
- Journal
- Scientific Reports
- Year
- 2022
- PMID
- 35688905
- Study Type
- Mouse
- Delivery
- Gas (Sustained Release)
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Japan
TL;DR
A silicon-based compound that releases hydrogen was found to help treat ulcerative colitis in mice by reducing inflammation and oxidative stress.
Key Finding
A silicon-based agent that generates hydrogen in the gastrointestinal tract reduced inflammation, oxidative stress, and both digestive and mental symptoms in mice with ulcerative colitis.
Summary
Researchers tested a silicon-based compound in mice with ulcerative colitis (a chronic inflammatory bowel disease). When ingested, this compound generated hydrogen gas in the digestive tract. The treatment reduced inflammation, oxidative stress (cellular damage from unstable molecules), and gastrointestinal symptoms in the mice. It also improved mood-related symptoms, suggesting the compound may work through connections between the gut and brain.
Practical Takeaway
While this early-stage mouse study suggests hydrogen-generating compounds may help with ulcerative colitis through multiple pathways, human studies are needed before any conclusions can be drawn. The findings are preliminary and do not yet support use of such compounds as a treatment in people.
Abstract (excerpt)
Ulcerative colitis (UC) is a non-specific inflammatory bowel disease that causes ulcers and erosions in the colonic mucosa and becomes chronic with cycles of amelioration and exacerbation. Because its exact etiology remains largely unclear, and the primary therapy is limited to symptomatic…